Evidence map›Paper›PMID 26189772›Full record

ArticleJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2016

Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways.

Megan M Weivoda, Ming Ruan, Christine M Hachfeld, Larry Pederson, Alan Howe, Rachel A Davey, Jeffrey D Zajac, Yasuhiro Kobayashi, Bart O Williams, Jennifer J Westendorf and 2 more

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 84 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 2 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 156 citations in OpenAlex.

  1. Consequences of Aging on Bone.Aging and disease · 2023
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2024 · on this map
    Review
  19. Multi-omics analyses reveal aberrant differentiation trajectory with WNT1 loss-of-function in type XV osteogenesis imperfecta.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2024
    Article
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Megan M WeivodaEndocrine Research Unit and Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.
Ming RuanEndocrine Research Unit and Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.
Christine M HachfeldEndocrine Research Unit and Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.
Larry PedersonEndocrine Research Unit and Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.
Alan HoweDepartment of Pharmacology, University of Vermont College of Medicine, Burlington, VT, USA.
Rachel A DaveyDepartment of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia.
Jeffrey D ZajacDepartment of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia.
Yasuhiro KobayashiInstitute for Oral Science, Matsumoto Dental University, Shiojiri, Nagano, Japan.
Bart O WilliamsCenter for Cancer and Cell Biology, Van Andel Institute, Grand Rapids, MI, USA.
Jennifer J WestendorfDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.
Sundeep KhoslaEndocrine Research Unit and Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.
Merry Jo OurslerEndocrine Research Unit and Kogod Center on Aging, Mayo Clinic, Rochester, MN, USA.
Mayo Clinic in Florida · USAustin Health · AUMatsumoto Dental University · JPMayo Clinic in Arizona · USUniversity of Vermont · USVan Andel Institute · US

Funding

SEX STEROIDS, GROWTH FACTORS, &BONE CELL FUNCTIONP01AG004875 · NIA · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 1985 to 2019
$30.8M
Musculoskeletal Research Training ProgramT32AR056950 · NIAMS · MAYO CLINIC ROCHESTER · PI Jennifer J Westendorf · 2009 to 2026
$7.0M
Analyzing the Role of Wnt Signaling in Bone DevelopmentR01AR053293 · NIAMS · VAN ANDEL RESEARCH INSTITUTE · PI WILLIAMS, BART O · 2007 to 2016
$4.0M
Osteoclast Regulation of Bone FormationR01AR067129 · NIAMS · MAYO CLINIC ROCHESTER · PI OURSLER, MERRY JO · 2015 to 2019
$3.0M
Canonical and Noncanonical Wnt Signaling in Osteoclast FunctionsR01AR065402 · NIAMS · MAYO CLINIC ROCHESTER · PI OURSLER, MERRY JO, WESTENDORF, JENNIFER J · 2015 to 2019
$2.4M
Runx2 and Axin2 Interactions During Bone FormationR01DE020194 · NIDCR · MAYO CLINIC ROCHESTER · PI WESTENDORF, JENNIFER J · 2010 to 2014
$2.1M
ROLE OF TGF-B INDUCIBLE EARLY GENE IN OSTEOCLASTOGENESISR01AR052004 · NIAMS · MAYO CLINIC ROCHESTER · PI OURSLER, MERRY JO · 2006 to 2010
$1.6M
Mechano-Chemical Regulation of GPCR/PKA Signaling During Cell MigrationR01GM117490 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HOWE, ALAN K · 2016 to 2019
$1.6M
Cross-talk between PKA, cellular tension, and Ca2+ channels during cell migrationR01GM097495 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI HOWE, ALAN K · 2011 to 2014
$1.2M
The Role of Podocalyxin in Osteoclast Activity and Bone MetabolismF32AR064679 · NIAMS · MAYO CLINIC ROCHESTER · PI WEIVODA, MEGAN M · 2013 to 2014
$84k
NIAMS NIH HHS F32 AR064679NIAMS NIH HHS R01 AR052004NIAMS NIH HHS R01 AR053293NIAMS NIH HHS R01 AR065402NIAMS NIH HHS R01 AR067129NIAMS NIH HHS T32 AR056950NIA NIH HHS P01 AG004875NIA NIH HHS P01 AG004875P3NIA NIH HHS P01 AG004875P4NIDCR NIH HHS R01 DE020194NIGMS NIH HHS R01 GM097495NIGMS NIH HHS R01 GM117490
6 · The paper itself

Abstract

Although there has been extensive characterization of the Wnt signaling pathway in the osteoblast lineage, the effects of Wnt proteins on the osteoclast lineage are less well studied. We found that osteoclast lineage cells express canonical Wnt receptors. Wnt3a reduced osteoclast formation when applied to early bone-marrow macrophage (BMM) osteoclast differentiation cultures, whereas late addition did not suppress osteoclast formation. Early Wnt3a treatment inactivated the crucial transcription factor NFATc1 in osteoclast progenitors. Wnt3a led to the accumulation of nuclear β-catenin, confirming activation of canonical Wnt signaling. Reducing low-density lipoprotein receptor-related proteins (Lrp) 5 and Lrp6 protein expression prevented Wnt3a-induced inactivation of NFATc1; however, deletion of β-catenin did not block Wnt3a inactivation of NFATc1, suggesting that this effect was mediated by a noncanonical pathway. Wnt3a rapidly activated the cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA) pathway and pharmacological stimulation of cAMP/PKA signaling suppressed osteoclast differentiation; Wnt3a-induced NFATc1 phosphorylation was blocked by inhibiting interactions between PKA and A-kinase anchoring proteins (AKAPs). These data indicate that Wnt3a directly suppresses osteoclast differentiation through both canonical (β-catenin) and noncanonical (cAMP/PKA) pathways in osteoclast precursors. In vivo reduction of Lrp5 and Lrp6 expressions in the early osteoclast lineage via Rank promoter Cre recombination reduced trabecular bone mass, whereas disruption of Lrp5/6 expression in late osteoclast precursors via cathepsin K (Ctsk) promoter Cre recombination did not alter the skeletal phenotype. Surprisingly, reduction of Lrp5/6 in the early osteoclast lineage decreased osteoclast numbers, as well as osteoblast numbers. Published studies have previously noted that β-catenin signaling is required for osteoclast progenitor proliferation. Our in vivo data suggest that Rank promoter Cre-mediated deletion of Lrp5/6 may similarly impair osteoclast progenitor proliferation.

Indexed as

A Kinase Anchor ProteinsAnimalsbeta CateninCell DifferentiationCyclic AMP-Dependent Protein KinasesEnzyme ActivationLow Density Lipoprotein Receptor-Related Protein-5Low Density Lipoprotein Receptor-Related Protein-6MiceNFATC Transcription FactorsOsteoclastsWnt3A ProteinA Kinase Anchor Proteinsbeta CateninCyclic AMP-Dependent Protein KinasesLow Density Lipoprotein Receptor-Related Protein-5Low Density Lipoprotein Receptor-Related Protein-6Lrp5 protein, mouseLrp6 protein, mouseNfatc1 protein, mouseNFATC Transcription FactorsWnt3A ProteinWnt3a protein, mouseOSTEOCLAST DIFFERENTIATIONPKAWNTβ-CATENIN

Identifiers

PMID26189772
PMCPMC4758681
OpenAlexW1927572613

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.